Otsuka Holdings

Otsuka Holdings' Integrated Report 2026 says technology validation has started to expand the Cysteinomix drug discovery platform using generative AI. In the same report, Taiho Pharmaceutical's Tsukuba discovery division says it is working to introduce robotics and AI in the search for drug targets and compound design while expanding Cysteinomix.

Otsuka Holdings' Integrated Report 2026 states that Astex is using a proprietary dataset of more than 19,000 protein-ligand complexes to develop computational co-folding capabilities called AstexFold and generative AI models for fragment-based and structure-based drug design. The report also mentions the Pyramid platform integrating AI/ML methods. This is company self-reported, and the report does not state a deployment stage.

Otsuka Pharmaceutical, K.K. eMind and Tohoku University announced Phase II of the Epilepsy Smart Medical collaborative research project. The release says the project applies eMind's AI prediction technology to epilepsy and that its objective is to support patients through digital devices and AI. Otsuka joined Phase II in April 2025.

Partners: K.K. eMind, Tohoku University

Otsuka Pharmaceutical and Shape TX announced a multi-target collaboration to develop intravitreally delivered AAVs for ocular diseases. The release describes Shape TX's AI-driven AAVid platform as combining screening of billions of AAV variants with machine learning to identify novel capsids, and says Shape TX is eligible for payments potentially exceeding $1.5 billion.

Partners: Shape TX